Progentos
progentos.com
Actively hiring
Cell & Gene Therapy
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Alta Partners
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Alta Partners Overview
Progentos Therapeutics is developing a new approach to treating multiple sclerosis that stimulates the body’s natural repair mechanisms.
News
Progentos Therapeutics Names Paul Frohna Chief Medical Officer
WATERTOWN, Mass., October 07, 2025--Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, today announced that Pau
Read more
Report
Progentos Therapeutics Appoints Andrew Miller, Ph.D. to Chairman of its Board of Directors
Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (...
Read more
Report
Progentos Therapeutics raises $65 million for multiple sclerosis
Chemical & Engineering News (C&EN): Keeping you up to date with the chemistry news that matters most. Published by the American Chemical Society.
Read more
Report
Progentos Therapeutics: $65 Million Raised To Address Unmet Needs To Regenerate Myelin And Restore Function For Patients With MS
Progentos Therapeutics, a biotechnology company addressing the unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, announced its launch and the closing of a $65 million series A
Read more
Report
Progentos Therapeutics Closes $65 Million Series A Financing to Advance Treatments for Multiple Sclerosis and Other Degenerative Diseases
Progentos Therapeutics Closes $65 Million Series A Financing to Advance Treatments for Multiple Sclerosis and Other Degenerative Diseases
Read more
Report
Progentos Therapeutics Closes $65 Million Series A Financing to Advance Treatments for Multiple Sclerosis and Other Degenerative Diseases
Read more
Report
Progentos Therapeutics Closes $65 Million Series A Financing to Advance Treatments for Multiple Sclerosis and Other Degenerative Diseases
Founded by Chief Executive Officer Chris Loose, Ph.D. and Chief Scientific Officer, Sanjay Magavi, Ph.D., Progentos to Drive Clinical Development of Novel Therapeutics for Remyelination Financing
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Watertown
United States
Regional office
200 Dexter Avenue, Watertown, MA, 02472, US